Co-Diagnostics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Co-Diagnostics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $105 per $100 of sales comes from others' credit, against $29 tied up three years earlier. Less money tied up than 97% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 2.7 times its market value (net cash). Higher than 97% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-28.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 63% of Healthcare companies in United States.
Cash Locked Ratio
−$105Money owed to suppliers is larger than money owed by customers plus stock: $105 per $100 of sales comes from others' credit, against $29 tied up three years earlier.
Less money tied up than 97% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 98%
Sales fell 98% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-98% / -80%In 3 years sales changed by -98% while total assets changed by -80%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-44.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 70% of Healthcare companies in United States.
Cash Cushion Ratio
2.7× cashCash, after subtracting all debt, is 2.7 times its market value (net cash).
Higher than 97% of Healthcare companies in United States.
Tangible Assets Ratio
71%Of every $100 the company owns, $71 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 61% of Healthcare companies in United States.
Tangible Net Worth Ratio
65%Of every $100 of net worth, $65 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 54% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Co-Diagnostics, Inc. made a loss over the last year. Co-Diagnostics, Inc. owes $0.23 for every $1 it owns. Co-Diagnostics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCo-Diagnostics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.31The share price is 0.31 times Co-Diagnostics, Inc.'s book value per share, lower than 96% of Healthcare companies in United States.
Market cap
$4 MThe total market value of all of Co-Diagnostics, Inc.'s shares at today's price (share price × number of shares), smaller than 95% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$13 MWhat Co-Diagnostics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.82Net worth divided by the number of shares. The share price of $0.57 is 0.3 times this, which is the P/B above.
Return on equity (ROE)
-174.8%Co-Diagnostics, Inc. lost 174.8% of its shareholders' money over the last year, lower than 82% of Healthcare companies in United States.
Owes vs Owns
0.23×Co-Diagnostics, Inc. owes $0.23 for every $1 it owns (low), lower than 68% of Healthcare companies in United States.
Dividend yield
NoneCo-Diagnostics, Inc. does not currently pay a dividend.
Revenue growth
-84%Revenue fell 84% in the year to Dec 2025, and shrank 74% a year on average over 3 years.
Profit growth
LossCo-Diagnostics, Inc. made a loss in each of the last two years.
Profit margin
-7533.6%Co-Diagnostics, Inc. lost $7534 for every $100 of revenue.
Cash vs debt
Net cashCo-Diagnostics, Inc. held $11 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Co-Diagnostics, Inc.: $4 M ÷ $13 M (30 Jun 2026) = 0.3.
What is Co-Diagnostics, Inc.'s return on equity?
Co-Diagnostics, Inc. lost 174.8% of its shareholders' money over the last year, lower than 82% of Healthcare companies in United States.
How much does Co-Diagnostics, Inc. owe compared with what it owns?
Co-Diagnostics, Inc. owes $0.23 for every $1 it owns (low), lower than 68% of Healthcare companies in United States.
Does Co-Diagnostics, Inc. pay a dividend?
No. Co-Diagnostics, Inc. does not currently pay a dividend.
Is Co-Diagnostics, Inc.'s revenue growing?
Revenue fell 84% in the year to Dec 2025, and shrank 74% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.